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Therapeutic Significance of 
1,4-Dihydropyridine Compounds 
as Potential Anticancer Agents
Tangali Ramanaik Ravikumar Naik
Abstract
A series of 1,4-dihydropyridines have been prepared from a three-component 
one-pot condensation reaction of β-diketonates, an aromatic aldehyde, and ammo-
nium acetate under microwave irradiation. The reaction is performed using crystal-
line nano-ZnO in ethanol under microwave irradiation (CEM discover). A wide 
range of functional groups was tolerated in the developed protocol. The present 
methodology offers several advantages such as simple procedure, greener condi-
tion, excellent yields and short reaction time. The synthesized compounds were 
evaluated for DNA photocleavage, SAR analysis and molecular docking studies. 
The compound (4b, 4c, 4 h, 4i, 4n and 4o) showed potent DNA cleavage activities 
compared to other derivatives. The molecular interactions of the active compounds 
within the binding site of B-DNA were studied through molecular docking simula-
tions; the compound (4b, 4c, 4 h, 4i, 4n and 4o) showed good docking interaction 
with minimum binding energies. All synthetic compounds were characterized by 
different spectroscopic techniques.
Keywords: 1,4-Dihydropyridines, DNA photocleavage, molecular docking, SAR 
analysis, ZnO nanoparticle
1. Introduction
Facile and efficient synthesis of biological active molecules is one of the main 
objectives of organic and medicinal chemistry. In recent years, multicomponent 
reactions have become one of the important tools in the synthesis of structurally 
diverse chemical libraries of drug-like polyfunctional organic molecules [1–4]. 
Furthermore, MCRs offer the advantage of simplicity and synthetic efficiency over 
conventional chemical reactions in several aspects. MCRs allow the construction of 
combinatorial libraries of complex organic molecules for an efficient lead structure 
identification and optimization in drug discovery [5–10].
In continuation of our ongoing research work on microwave assisted synthesis 
of nano materials [11, 12] we have found that, nano-crystalline metal oxides have 
attracted considerable attention of synthetic and medicinal chemists because of 
their high catalytic activity and reusability [13–25]. Zinc oxide is an inexpensive, 
moisture stable, reusable, commercially available and is non-toxic, insoluble in 
polar as well as non-polar solvents [26–31]. A wide range of organic reactions 
that include Beckmann rearrangements [32], N-benzylation [33], acylation [34], 
dehydration of oximes [35], nucleophilic ring opening reactions of epoxides [36], 
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synthesis of cyclic urea [37], N-formylation of amines [38]. In particular crystal-
line nano-ZnO oxide exhibit better catalytic activity compared to their bulk sized 
counterparts [29, 39–42].
In recent years, much attention has been directed toward the synthesis of dihy-
dropyridine compounds owing to their tremendous application in various research 
fields including biological science and medicinal chemistry [43, 44]. Many DHPs 
are already commercial products such as: amlodipine, felodipine, isradipine, laci-
dipine, nicardipine, nitrendipine, nifedipine and nimodipine B, of which nitren-
dipine and nemadipine B exhibit potent calcium channel blocking activities [45–49] 
(Figure 1) and have emerged as one of the most important classes of drugs for the 
treatment of cardiovascular diseases [50, 51]. Moreover dihydropyridine deriva-
tives possess a variety of biological activities like, geroprotective, hepatoprotective, 
anti-atherosclerotic, antitumor, and antidiabetic activities [46, 52, 53]. Widespread 
studies have uncovered that dihydropyridine unit containing compounds exhibit 
various medicinal functions such as neuroprotectant, platelet anti-aggregatory 
activity, cerebral anti ischemic activity in the treatment of Alzheimer’s disease, 
chemosensitizer in tumor therapy [54–56]. Drug-resistance modifiers [57], antioxi-
dants [58] and a drug for the treatment of urinary urge incontinence [59].
In order to model and understand these biological properties and to develop 
new chemotherapeutic agents based upon the 1,4-DHP compounds, significant 
effort has been devoted to establish effective methods for their synthesis. Generally, 
1,4-DHPs were synthesized by Hantzsch method [60], which involves cyclocon-
densation of an aldehyde, a β-ketoester and ammonia either in acetic acid or under 
reflux in alcohols for long reaction times which typically leads to low yields [46, 61, 
62]. Other methods comprise the use of microwaves [63–65], high temperatures at 
reflux [66–69], organocatalysts [70] and metal triflates [71].
Recently, DNA is an important drug target and it regulates many biochemical 
processes that occur in the cellular system. Small-molecule interactions with DNA 
continue to be intensely and widely studied for their usefulness as probes of cellular 
replication and transcriptional regulation and for their potential as pharmaceuticals 
[72–75]. In particular, designing of the compound based on their ability to cleave 
DNA is of great importance not only from the primary biological point of view 
Figure 1. 
Drugs containing 1,4-DHP moieties.
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but also in terms of photodynamic therapeutic approach to develop potent drugs 
[72–75]. 1,4-Dihydropyridine derivatives have attracted the attention of the chem-
ists because of their diverse biological applications [76]. The biological significance 
of this class of compounds impelled us to extend this series by working on the 
synthesis and DNA photocleavage studies of 1,4-dihydropyridine derivatives. In 
this communication, synthesis of 1,4-dihydropyridine derivatives and their DNA 
photocleavage studies and molecular docking have been reported.
In literature, there are several methods known for the synthesis of 1,4-dihy-
dropyridine derivatives. In continuation of our program on the chemistry of nano 
material, herein we report an efficient microwave method for the synthesis of 
crystalline ZnO-NPs. The ZnO used in this work was synthesized according to a 
modified method. The prepared crystalline ZnO-nano-particle was characterized 
using powder XRD, SEM, EDX (Figure 2). Our synthetic approach started with the 
condensation of 1 equiv. of benzaldehyde 1a with 2 equiv. of ethyl acetoacetate 2a 
and 2 equiv. of NH4OAc 3a in the presence of ZnO-Nps resulted in the formation of 
Hantzsch 1,4-dihydropyridine 4a (Figure 3). The reaction was complete in 5 min 
under microwave irradiation and the product was isolated by the usual work-up, in 
90% yield and high purity. Under similar conditions, various substituted aromatic 
aldehydes carrying either electron-donating or -withdrawing substituents reacted 
with 1,3-diketones to form 1,4-DHPs in good to excellent yields, and the results are 
summarized in Table 1.
A microwave irradiation-assisted process very often minimizes the formation 
of byproducts and requires much less time than thermal methods. The main ben-
efits of performing reactions under controlled conditions in sealed vessels are the 
significant rate enhancements and the higher product yields that can frequently 
be achieved. Therefore, in continuation of our studies on microwave synthesis 
of nano-materials [77–81], we have attempted to develop a rapid, microwave-
assisted protocol for the synthesis of 1,4-DHPs using crystalline ZnO-nano 
catalyst (Figure 3).
The DNA cleavage of 1,4-DHP derivatives were studied by agarose gel electro-
phoresis. When circular plasmid DNA was subjected to electrophoresis, relatively 
fast migration was observed for the intact supercoiled DNA (type I). If scission 
occurs on one strand (nicking), the supercoiled DNA will relax to generate a slower 
moving open circular form (type II). If both strands are cleaved, a linear form 
Figure 2. 
(a) Powder XRD of obtained ZnO nano particles by microwave method; (b) SEM images of ZnO-NPs;  
(c) EDX analysis spectrum of obtained ZnO nano particles by microwave method.
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(type III) that migrates between type I and type II will be generated [82–85]. The 
conversion of type I (supercoiled) to type II (nicked circular) was observed with 
different concentration of 1,4-DHP and irradiated for 2 h, in 1:9 DMSO/trisbuffer 
(20 μM, pH- 7.2) at 365 nm. No DNA cleavage was observed for the control in which 
1,4-DHP was absent (lane 1) (Figure 4). With increasing concentration of these 
1,4-DHP the amount of type I of pUC 19 DNA diminished gradually, whereas type 
II increased (Figure 4).
At 40 μM concentration, the Compound (4c) can promote only 30% conversion 
of DNA from type I to II (Figure 5). At the concentration of 80 μM, compound (4c) 
Figure 3. 
Synthesis of 1,4-dihydropyridines.
Entrya R R1 Products Entrya Yield (%)b
1 C6H5 t-Bu 4a 1 90
2 4-MeO-C6H5 t-Bu 4b 2 95
3 4-OH-C6H5 t-Bu 4c 3 95
4 4-F-C6H5 t-Bu 4d 4 95
5 4-Cl-C6H5 t-Bu 4e 5 90
6 4-NO2-C6H5 t-Bu 4f 6 95
7 C6H5 Et 4 g 7 90
8 4-MeO-C6H5 Et 4 h 8 95
9 4-OH-C6H5 Et 4i 9 92
10 4-F-C6H5 Et 4j 10 92
11 4-Cl-C6H5 Et 4 k 11 90
12 4-NO2-C6H5 Et 4 l 12 90
13 C6H5 Me 4 m 13 90
14 4-MeO-C6H5 Me 4n 14 87
15 4-OH-C6H5 Me 4o 15 90
16 4-F-C6H5 Me 4p 16 90
17 4-Cl-C6H5 Me 4q 17 90
18 4-NO2-C6H5 Me 4r 18 90
aAll the products were characterized by 1H NMR and 13C NMR studies and compared with the literature mps. 
bYields of isolated products
Table 1. 
Synthesis of 1,4-dihydropyridines.
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can almost promote the about 80% conversion of DNA from type I to II (Figure 5). 
The cleavage potential of the test compounds were assessed by comparing the bands 
appeared in control and test compounds at 80 μM concentration. However, other 
derivatives exhibits much lower cleaving efficiency for pUC 19 DNA. Even at the 
concentration of 80 μM, it can promote only 40% conversion of DNA from type I to 
II (Figure 5).
But at higher concentrations around 130 μM, the compounds get precipitated 
and there is no moment in the DNA. The image (Figure 6) clearly demonstrates 
that compounds (4b, 4c, 4d, 4e, 4f and 4 g) shows DNA cleavage of pUC19 DNA 
at 80 μM concentration. The results indicated that compounds bearing –OCH3 and 
–OH at -para position of phenyl ring (C-6) did cleave the DNA completely, other 
compounds have displayed nearly complete cleavage of DNA. Overall, it indicates 
that, the alkoxy groups are highly reactive radicals, which abstracts hydrogen atoms 
efficiently at C-4′ of 2-deoxyribose. It is of interest to note that hydroxyl group has 
been reported to bring about oxygen radical mediated DNA damage in the presence 
of photoirradiation [86].
The structure–activity relationship studies of 1,4-DHPs with regard to DNA 
photocleavage studies shows that, the changes in the substitution pattern at C-3, 
C-4, and C-5 positions alter the 1,4-DHP ring. Osiris Property Explorer is one such 
knowledge based activity prediction tool which predicts drug likeliness, drug score 
and undesired properties such as mutagenic, tumorigenic, irritant and reproductive 
effect of novel compounds based on chemical fragment data of available drugs and 
non-drugs as reported (Table 2) [87]. It was observed that, the compounds having 
aliphatic groups such as –CH3, –COOCH3, –COOC2H5 and –COOC(CH3)3, attached 
to C-2 and C-3 of 1,4-DHP exhibited good activity. Other derivatives possessing, 
an electron-donating substituent, such as hydroxy and methoxy group on the 
phenyl ring (C-6) increases DNA photocleavage activity. A lone pair of electrons 
on oxygen atom of methoxy group delocalizes into the π space of benzene ring, 
Figure 4. 
Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: 
Control DNA (with out compound), lane; 2: 20 μM (4c), lane; 3: 40 μM (4c), lane; 4: 60 μM (4c), lane; 5: 
80 μM (4c).
Figure 5. 
Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: 
Control DNA (with out compound), lane; 2: 40 μM (4a), lane; 3: 40 μM (4b), lane; 4: 40 μM (4c), lane; 5: 
40 μM (4d), lane; 5: 40 μM (4e), lane; 5: 40 μM (4f), lane; 5: 40 μM (4 g).
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thereby increasing the activity. Similarly, electron-withdrawing substituent’s, such 
as 4-fluorophenyl, 4-chloro phenyl of 1,4-DHP lower the activity. These results 
indicate that, the alkoxy substituent’s and nitrogen of pyridine ring in the 1,4-DHP 
structure are the responsible for DNA cleavage.
In order to rationalize the observed spectroscopic results and to get more insight 
into the intercalation modality, the 1,4-DHP (4a–r) were successively docked 
[88–90] within the DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer 
Figure 6. 
Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: 
Control DNA (with out compound), lane; 2: 80 μM (4a), lane; 3: 80 μM (4b), lane; 4: 80 μM (4c), lane; 5: 
80 μM (4d), lane; 5: 80 μM (4e), lane; 5: 80 μM (4f), lane; 5: 80 μM (4 g).
Compounds Mol. wt C log P Drug-
likeness
Drug-
score
Toxicity risksa
Mb Tc Id Re
4a 329 3.29 2.41 0.77 (+) (+) (+) (+)
4b 359 3.22 2.34 0.75 (+) (+) (+) (+)
4c 345 2.94 2.48 0.79 (+) (+) (+) (+)
4d 347 3.39 1.65 0.70 (+) (+) (+) (+)
4e 419 5.37 −17.92 0.22 (+) (+) (+) (+)
4f 430 4.17 −19.36 0.10 (−) (+) (+) (−)
4 g 301 2.48 4.04 0.87 (+) (+) (+) (+)
4 h 331 2.41 3.87 0.51 (+) (+) (+) (+)
4i 317 2.13 4.08 0.53 (+) (+) (+) (+)
4j 319 2.58 3.29 0.50 (+) (+) (+) (+)
4 k 363 3.89 3.33 0.68 (+) (+) (+) (+)
4 l 374 2.69 1.92 0.25 (−) (+) (+) (−)
4 m 269 2.98 4.09 0.50 (+) (+) (+) (+)
4n 299 2.91 3.94 0.49 (+) (+) (+) (−)
4o 285 2.63 4.14 0.51 (+) (+) (+) (+)
4p 287 3.08 3.42 0.47 (+) (+) (+) (−)
4q 335 3.08 4.97 0.48 (+) (+) (+) (−)
4r 346 1.88 3.50 0.30 (−) (+) (+) (−)
aRanking as (+) no bad effect, (+/−) medium bad effect, (−) bad effect. 
bM (mutagenic effect); 
cT (tumorigenic effect); 
dI (irritant effect);  
eR (reproductive effect).
Table 2. 
Drug likeliness properties of 1,4-dihydro pyridines according to Osiris property explorer tool.
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(PDB ID: 1BNA) in order to predict the chosen binding site along with preferred 
orientation of the ligand inside the DNA minor groove. All synthesized 1,4-DHP 
derivatives were drawn in ChemSketch and structures were saved in .mol format. 
Afterwards the .mol format was used in Hyperchem-7, to adjust their fragments, 
followed by total energy minimization of ligands so that they can attain a stable 
conformation and the file was saved in .pdb format.
Protein 3D structure of B-DNA was obtained from RCSB PDB (an information 
portal to biological macromolecular structures). The water molecules were removed 
from the file, and the protein was protonated in 3D to add polar hydrogen’s. Binding 
pocket was identified using site finder, and the respective residues were selected. 
Docking parameters were set to default values and scoring algorithm, the docking 
runs were retained to 30 conformations per ligand. The docked protein structures 
were saved in .pdb format, and ligand’s conformations were investigated one by 
one. Complexes with best conformations were selected on the basis of highest score, 
lowest binding energy and minimum RMSD values [91].
The synthesized organic compounds perform their biological activity more effi-
ciently by binding respective protein or DNA at their specific binding site. Identification 
of interacting residues with ligands is a necessary step toward rational drug designing, 
understanding of molecular pathway and mechanistic action of protein.
Molecular docking was carried out between rigid receptor protein and the flex-
ible ligands. Table 3 shows the details of the docking results including RMSD and 
binding energy values of protein–ligand complexes. The ligands (4b, 4c, 4 h, 4i, 
4n and 4o) bind strongly to B-DNA as inferred by their minimum binding energy 
values, that is, −13.8, −12.9 and − 12.3 kcal/mol, respectively (Figure 7).
Figure 8 shows the position of active site in the helical structure of DNA and it 
also shows that all docked ligands clustered inside the pocket. Figure 8 exhibited 
Products Docking energy (Kcal/mol) Inhibition constant (M) RMSD
4a −6.23 4.35 × 10−7 2.5
4b −24.12 1.81 × 10−16 1.1
4c −21.74 1.96 × 10−16 1.5
4d −5.72 5.96 × 10−7 3.4
4e −7.24 6.31 × 10−7 3.4
4f −6.85 4.88 × 10−7 3.8
4 g −7.41 4.51 × 10−7 2.0
4 h −22.35 1.92 × 10−16 1.0
4i −19.81 2.32 × 10−16 1.0
4j −6.34 5.88 × 10−7 2.1
4 k −6.68 6.76 × 10−7 2.1
4 l −8.22 5.18 × 10−7 2.4
4 m −7.55 4.68 × 10−7 2.3
4n −22.64 1.96 × 10−16 1.1
4o −20.36 2.18 × 10−16 1.0
4p −6.78 6.20 × 10−7 1.5
4q −6.52 7.15 × 10−7 1.8
4r −7.89 6.32 × 10−7 1.5
Table 3. 
Molecular docking studies of 1,4-dihydropyridines.
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the hydrogen bond interaction of 4c and 4d with key residues in active site inside 
the helical structure of DNA. In this model, it is clearly indicated that the com-
pound 4c formed hydrogen bonded between the –OH and N1 of thymine, which is 
DT7 and DT19 with the bond length of 2.02 and 2.05 Ǻ respectively. Moreover, the 
other derivatives of 1,4-DHP formed less H-bond interaction with the DNA due to 
the orientation of aromatic ring involved in van der Waals interactions (Wireframe 
model) and flat hydrophobic regions of the binding sites of DNA (Table 3). These 
results demonstrated the in silico molecular docking studies of 1,4-DHPs with 
B-DNA suggested that 1,4-DHPs possess the potential to disturb hydrophobic and 
H-bond interactions thereby affecting the stability of attachment of B-DNA, and 
may be effective for cancer cell lines.
Figure 7. 
1,4-DHP was successively docked within the DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer 
(PDB ID: 1BNA).
Figure 8. 
Interaction of 1,4-DHP with DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA).
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2. Experimental
2.1 Materials and method
All the chemicals used in the present study are of AR grade. Whenever analyti-
cal grade chemicals were not available, laboratory grade chemicals were purified 
and used. AlCl3, ZnCl2, Yb(OTF)3, FeCl3 and Zinc acetate obtained from Merck 
chemicals and are directly used without further purification. Melting points were 
recorded on an open capillary tube with a Buchi melting point apparatus and are 
uncorrected. 1H- NMR spectra were obtained using a 400 MHz on a Bruker spec-
trometer (chemical shifts in δ ppm).
2.1.1 General procedure for the preparation of ZnO-Nps
In a typical synthesis process, zinc acetate dihydrate (1.1 g, 0.01 M) was dis-
solved in 20 mL of ethanol with constant stirring for 20 min. Then KOH (0.178 M) 
was added into the above mixed solution. After further stirring for 5 min, the reac-
tion mixture was put into a CEM microwave synthesizer to irradiate for 10 min with 
the power set at 150 W, Temperature at 150°C and Pressure 150 C0. After comple-
tion of reaction, the white precipitate was collected by centrifugation, washed twice 
with deionized water, ethanol and dried in vacuum oven at 60°C for 5 h.
Crystalline structure of the prepared ZnO-Nps was determined by powder X-ray 
diffraction (XRD). The strong intensity and narrow width of diffraction peaks 
indicate the high crystallinity of the prepared ZnO-Nps (Figure 2a). The peaks are 
indexed as 31.82° (100), 34.54° (002), 36.42° (101), 47.46° (102), 56.74° (110), 62.92° 
(103), 66.06° (200), 68.42° (112), 69.06° (201) and 78.82° (202) respectively. This 
revealed that the resultant nanoparticles were pure ZnO with a hexagonal structure 
(JCPDS 36-1451). No impurities could be detected in this pattern, which implies 
hexagonal phase ZnO nanoparticles could be obtained under the current microwave 
method. X-ray diffraction shows that metal oxide is pure ZnO having hexagonal 
structure. Sharpness of the peaks shows good crystal growth of the oxide particles. 
Average particle sizes of the ZnO have been calculated using from high intensity 
peak using Image J.
2.1.2 General procedure for the synthesis of 1,4-DHP by microwave method
A mixture of aromatic aldehydes 1a (5 mmol), ethyl acetoacetate 2 (10 mmol), 
and ammonium acetate 3 (10 mmol) and ZnO (10 mol %) was taken in ethanol 
(20 mL) and the mixture was heated at microwave irradiation for 5 min (monitored 
by TLC after 5 min. interval). After 5 min, the reaction mixture was cooled to room 
temperature and then it was poured into cold water. The product was extracted 
with ethyl acetate. The organic layer was washed with brine, water and dried over 
anhydrous Na2SO4. The crude product thus obtained was recrystallized from EtOH 
to obtain desired product (Figure 3, Table 1).
4a.  Di-tert-Butyl − 1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3,5- 
dicarboxylate
Solid: MP 180–182°C; 1H NMR (500 MHz, CDCl3) δ 1.43 (s, 18H), 2.30 (s, 6H), 
4.83 (s, 1H), 5.58 (brs, 1H), 7.05-7.10 (m, 1H), 7.10-7.20 (m, 2H), 7.23-7.30 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ 20.0, 28.4, 40.0, 80.0, 105.5, 125.6, 127.5, 128.5, 129.2, 
143.0, 147.5, 167.3.
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4b.  Di-tert-butyl 4-(4-methoxyphenyl)-l,4-dihydro-2,6-dimethylpyridine-
3,5-dicarboxylate
Solid: MP 168–170°C; 1H NMR (500 MHz, CDCl3) δ 1.40 (s, 18H), 2.25 (s, 6H), 
3.86 (s, 3H), 4.81 (s, 1H), 5.51 (brs, 1H), 7.10-7.20 (d, 2H), 7.40-7.50 (d, 2H); 13C 
NMR (125 MHz, CDCl3) δ 19.8, 30.0, 41.0, 56.0, 81.0, 106.1, 125.6, 127.8, 135.0, 
146.4, 153.2, 160.0, 167.5.
4c.  Di-tert-butyl 4-(4-hydroxy-phenyl)-l,4-dihydro-2,6-dimethylpyridine-
3,5-dicarboxylate
Solid: MP 230–232°C; 1H NMR (500 MHz, CDCl3) δ 1.36 (s, 18H), 2.28 (s, 6H), 
4.90 (s, 1H), 5.56 (brs, 1H), 6.86-6.90 (d, 2H), 7.10-7.20 (d, 2H), 10.10 (s, 1H); 13C 
NMR (125 MHz, CDCl3) δ 24.5, 32.8, 45.3, 88.0, 108.4, 128.3, 131.0, 134.2, 134.6, 
136.8, 148.4, 154.6, 172.6.
4d.  Di-tert-butyl − 4-(4-fluorophenyl)-l,4-dihydro-2,6-dimethylpyridine-
3,5-dicarboxylate
Solid: MP 150–152°C; 1H NMR (500 MHz, CDCl3) δ 1.43 (s, 18H), 2.30 (s, 
6H), 4.81 (s, 1H), 5.50 (brs, 1H), 6.90-6.96 (d, 2H), 7.15-7.20 (d, 2H); 13C NMR 
(125 MHz, CDCl3) δ 20.0, 21.3, 38.9, 40.0, 79.8, 106.0, 114.2, 113.7, 125.4, 126.8, 
129.2, 142.5, 143.2, 160.0, 162.5, 167.1.
4e.  Di-tert-butyl 4-(4-chlorophenyl)-l,4-dihydro-2,6-dimethylpyridine-
3,5-dicarboxylate
Solid: MP 188–190°C; 1U NMR (500 MHz, CDCl3) δ 1.38 (s, 18H), 2.25 (s, 6H), 
4.85 (s, 1H), 5.50 (brs, 1H), 6.80-6.85 (d, 2H), 7.00-7.08 (d, 2H); 13C NMR (125 MHz, 
CDCl3) δ 24.3, 33.4, 45.1, 86.2, 108.8, 128.9, 130.4, 133.5, 134.3, 136.1, 148.6, 151.6, 172.4.
4 f.  Di-tert-butyl − 4-(4-nitrophenyl)-l,4-dihydro-2,6-dimethylpyridine-
3,5-dicarboxylate
Solid: MP 176–178°C; 1H NMR (500 MHz, CDCl3) δ 1.38 (s, 18H), 2.30 (s, 6H), 
4.86 (s, 1H), 5.55 (brs, 1H), 7.00–7.10 (d, 2H), 7.15–7.25 (d, 2H); 13C NMR (125 
MHz, CDCl3) δ 20.5, 22.4, 38.6, 40.1, 79.6, 107.0, 114.5, 114.6, 126.2, 126.8, 129.6, 
142.6, 144.6, 161.0, 167.1.
4 g.  2,6-Dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid  
diethyl ester
Solid: MP 158–160°C; 1H NMR (CDCl3, 400 MHz): δ 1.20 (t, J = 9.7 Hz, 6H, 
2CH3CH2), 2.28 (s, 6H, 2CH3), 4.10 (q, J = 6 Hz, 4H, 2CH3CH2), 5.00 (s, 1H, 
CH), 5.75 (s, 1H, NH), 7.10–7.50 (m, 5H); 13C NMR (CDCl3, 75 MHz): δ = 14.20 
(C-3″), 19.5 (C-1″), 39.6 (C-4), 59.5 (C-2″), 104.1 (C-3 and C-5), 126.0 (C-4′),  
127.8 (C-3′ and C-5′), 130.0 (C-2′ and C-6′), 143.8 (C-2 and C-6), 148.0 (C-1′), 
168.0 (C-4″).
4 h.  2,6-Dimethyl-4-(4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5-
dicarboxylic acid diethyl ester
Solid: MP 160–162°C; 1H NMR (CDCl3, 400 MHz): δ 1.21 (t, J = 7.0 Hz, 6H), 
2.30 (s, 6H), 3.78 (s, 3H), 4.10 (q, J = 6.3 Hz, 4H), 4.95 (s, 1H), 5.60 (s, 1H), 6.80 
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(d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.7 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 19.6, 
38.8, 55.2, 59.8, 104.0, 115.0, 128.8, 140.0, 145.3, 156.7, 168.0.
4i.  2,6-Dimethyl-4-(4-hydroxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid diethyl ester
Solid: MP 238–240°C; 1H NMR (CDCl3, 400 MHz): δ 1.18 (t, J = 7.2 Hz, 6H), 2.28 
(s, 6H), 4.05 (q, J = 6.6 Hz, 4H), 4.90 (s, 1H), 5.61 (s, 1H), 6.70 (d, J = 8.7 Hz, 2H), 
7.15 (d, J = 8.4 Hz, 2H), 9.90 (s, 1H); 13C NMR (CDCl3, 75 MHz): δ 14.0, 18.9, 39.0, 
59.0, 103.0, 114.2, 128.3, 139.4, 144.2, 154.1, 167.6.
4j.  2,6-Dimethyl-4-(4-fluoro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid diethyl ester
Solid: MP 152–154°C; 1H NMR (CDCl3, 400 MHz): δ 1.10 (t, J = 7.2 Hz, 6H), 2.25 
(s. 6H), 4.00 (q, J = 5.7 Hz, 4H), 4.88 (s, 1H), 5.68 (s, 1H), 6.80 (m, 2H), 7.15(m, 
2H); 13C NMR (CDCl3, 75 MHz): δ 14.3, 19.7, 39.6, 60.1, 104.2, 114.4, 129.4, 129.7, 
130.0, 143.5, 147.0, 167.5.
4 k.  2,6-Dimethyl-4-(4-chloro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid diethyl ester
Solid: MP 153–155°C; 1H NMR (CDCl3, 400 MHz): δ 1.12 (t, J = 7.2 Hz, 6H), 2.35 
(s. 6H), 4.12 (q, J = 5.7 Hz, 4H), 5.10 (s, 1H), 5.82 (s, 1H), 7.50 (d, 2H), 8.16 (d, 2H); 
13C NMR (CDCl3, 75 MHz): δ 14.2, 18.6, 39.6, 60.0, 101.6, 116.8, 127.8, 129.3, 130.2, 
144.8, 147.2, 166.8.
4 l.  2,6-Dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid diethyl ester
Solid: MP 178–180°C; 1H NMR (CDCl3, 400 MHz): δ 1.26 (t, J = 7.2 Hz, 6H), 2.35 
(s. 6H), 4.06 (q, J = 5.7 Hz, 4H), 5.08 (s, 1H), 5.76 (s, 1H), 7.48 (m, 2H), 8.02 (m, 
2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 19.5, 39.6, 59.6, 104.2, 121.3, 1234.0, 128.4, 
136.8, 144.5, 147.8, 148.8, 167.5.
4 m.  2,6-Dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 
dimethyl ester
Solid: MP 194–196°C; 1H NMR (CDCl3, 400 MHz): δ 2.30 (s, 6H, 2CH3), 3.66 
(s, 6H, 2CH3), 5.00 (s, 1H, CH), 5.80 (b, 1H), 7.20-7.56 (m, 5H); 
13C NMR (CDCl3, 
75 MHz): δ = 19.7, 38.7, 50.5, 105.5, 126.2, 127.0, 128.0, 144.1, 147.1, 168.2.
4n.  2,6-Dimethyl-4-(4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5-
dicarboxylic acid dimethyl ester
Solid: MP 185–187°C; 1H NMR (CDCl3, 400 MHz): δ 2.28 (s, 6H, 2CH3), 3.60 (s, 
6H, 2CH3), 3.78 (s, 3H), 4.89 (s, 1H, CH), 5.30 (b, 1H), 6.80–7.10 (m, 4H); 
13C NMR 
(CDCl3, 75 MHz): δ 19.5, 38.7, 55.1, 51.8, 104.4, 113.2, 128.9, 140.4, 143.4, 158.0, 167.7.
4o.  2,6-Dimethyl-4-(4-hydroxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid dimethyl ester
Solid: MP 228–230°C; 1H NMR (CDCl3, 400 MHz): δ 2.26 (s, 6H, 2CH3), 3.63 
(s, 6H, 2CH3), 5.00 (s, 1H, CH), 5.40 (b, 1H), 6.95–7.20 (m, 4H); 
13C NMR (CDCl3, 
75 MHz): δ 18.4, 38.4, 51.8, 103.1, 114.2, 128.4, 139.0, 144.2, 155.0, 167.6.
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4p.  2,6-Dimethyl-4-(4-fluoro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid dimethyl ester.
Solid: MP 170–172°C; 1H NMR (CDCl3, 400 MHz): δ 2.32 (s, 6H, 2CH3), 3.64 (s, 
6H, 2CH3), 4.98 (s, 1H, CH), 5.78 (b, 1H), 7.10 (t, 2H), 7.32 (t, 2H); 
13C NMR (CDCl3, 
75 MHz): δ 19.5, 40.0, 51.0, 104.1, 114.4, 129.3, 130.0, 144.1, 145.3, 160.5, 162.3, 167.6.
4q.  2,6-Dimethyl-4-(4-chloro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid dimethyl ester
Solid: MP 194–196°C; 1H NMR (CDCl3, 400 MHz): δ 2.30 (s, 6H, 2CH3), 3.66 
(s, 6H, 2CH3), 4.95 (s, 1H, CH), 5.76 (b, 1H), 7.15 (m, 2H), 7.36 (m, 2H); 
13C NMR 
(CDCl3, 75 MHz): δ 19.5, 39.6, 51.1, 103.6, 113.8, 128.2, 130.0, 144.4, 146.2, 160.4, 167.8.
4r.  2,6-Dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic 
acid dimethyl ester
Solid: MP 210–212°C; 1H NMR (CDCl3, 400 MHz): δ 3.00 (s, 6H, 2CH3), 3.61 
(s, 6H, 2CH3), 5.08 (s, 1H, CH), 5.86 (b, 1H), 7.30 (m, 2H), 7.62 (m, 2H); 
13C NMR 
(CDCl3, 75 MHz): δ 19.7, 40.1, 51.2, 103.2, 114.4, 128.7, 145.0, 146.1, 156.2, 167.6.
3. Conclusion
In conclusion, the present study describes the ZnO-NPs catalyzed synthesis of 
1,4-dihydropyridines (4a–r) under microwave irradiation, giving excellent yields 
in shorter reaction time as compared to conventional method. All the synthesized 
compounds were evaluated for DNA photocleavage, SAR and DNA docking studies. 
DNA cleavage by gel electrophoresis method revealed that compounds (4b and 4c) 
were found to cleave the DNA completely. The preliminary SAR study revealed that 
the –OCH3 and –OH substituted compounds, were more favorable for activity, par-
ticularly at -para position of the phenyl ring. Docking studies indicated that one of 
the ester moieties of these compounds played a key role in their interactions with the 
DNA. However, the nature of reactive intermediates involved in the DNA cleavage by 
the 1,4-dihydropyridines has not been clear. Needless to say, further understanding 
the mechanism of biological action are still required in order to fully develop these 
compounds as potent anticancer drugs.
Acknowledgements
We are grateful to Prof. H. S. Bhojya Naik, Department of Industrial chemistry, 
Kuvempu University, for his suggestions, and CeNSE, Indian Institute of science, 
Bangalore, for providing all necessary facility to carry-out this result.
13
Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents
DOI: http://dx.doi.org/10.5772/intechopen.89860
Author details
Tangali Ramanaik Ravikumar Naik
Vijayanagara Srikrishna Devaraya University (VSKU), Ballari, Karnataka
*Address all correspondence to: naikravi7@gmail.com
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
14
Organic Synthesis - A Nascent Relook
References
[1] Raman DJ, Yus M. Asymmetric 
multicomponent reactions (AMCRs): 
The new frontier. Angewandte Chemie, 
International Edition. 2005;44:1602
[2] Domling A. Recent developments 
in isocyanide based multicomponent 
reactions in applied chemistry. 
Chemical Reviews. 2006;106:17
[3] Domling A, Ugi I. Multicomponent 
Reactions with Isocyanides. 
Angewandte Chemie, International 
Edition. 2000;39:3168
[4] Zhu J, Bienayme H, editors. 
Multicomponent Reaction. Weinheim: 
Wiley-VCH; 2005
[5] Tanaka K, Toda F. Solvent-free 
organic synthesis. Chemical Reviews. 
2000;100:1025
[6] Li C-J. Organic reactions in aqueous 
media with a focus on carbon-carbon 
bond formations: A decade update. 
Chemical Reviews. 2005;105:3095
[7] Paul S, Bhattacharyya P, Das AR. One-
pot synthesis of dihydropyrano[2,3-c]
chromenes via a three component 
coupling of aromatic aldehydes, 
malononitrile, and 3-hydroxycoumarin 
catalyzed by nano-structured ZnO in 
water: A green protocol. Tetrahedron 
Letters. 2011;52:4636-4641
[8] Ghosh PP, Das AR. Nano crystalline 
ZnO: A competent and reusable 
catalyst for one pot synthesis of novel 
benzylamino coumarin derivatives in 
aqueous media. Tetrahedron Letters. 
2012;53:3140
[9] Bhattacharyya P, Pradhan K, Paul S, 
Das AR. Nano crystalline ZnO catalyzed 
one pot multicomponent reaction for an 
easy access of fully decorated 4H-pyran 
scaffolds and its rearrangement to 
2-pyridone nucleus in aqueous media. 
Tetrahedron Letters. 2012;53:4687
[10] Ghosh PP, Pal G, Paul S, Das AR. 
Design and synthesis of benzylpyrazolyl 
coumarin derivatives via a four-
component reaction in water: 
Investigation of the weak interactions 
accumulating in the crystal structure of 
a signified compound. Green Chemistry. 
2012;14:2691
[11] Jena A, Vinu R, Shivashankar SA, 
Giridhar M. Microwave assisted 
synthesis of nanostructured 
titanium dioxide with high 
photocatalytic activity. Industrial and 
Engineering Chemistry Research. 
2010;49(20):9636-9643
[12] Sai R, Kulkarni SD, Vinoy KJ, 
Bhat N, Shivashankar SA. ZnFe2O4: 
Rapid and sub-100°C synthesis and 
anneal-tuned magnetic properties. 
Journal of Materials Chemistry. 
2012;22:2149-2156
[13] Reddy KH, Reddy VVP, 
Shankar J, Madhav B, Kumar BSPA, 
Nageswar YVD. Copper oxide 
nanoparticles catalyzed synthesis of 
aryl sulfides via cascade reaction of 
aryl halides with thiourea. Tetrahedron 
Letters. 2011;52:2679-2682
[14] Cristau H-J, Cellier PP, Spindler J-F, 
Taillefer M. Highly efficient and mild 
coppercatalyzed N- and C-arylations 
with aryl bromides and iodides. 
Chemistry. 2004;10(22):5607-5622
[15] Mittapelly N, Reguri BR, Mukkanti K. 
Copper oxide nanoparticles-catalyzed 
direct Nalkylation of amines with alcohols. 
Der Pharma Chemica. 2011;3:180-189
[16] Chassaing S, Kumarraja M, Sido ASS, 
Pale P, Sommer J. Click chemistry in 
CuI-zeolites: The Huisgen [3 + 2]- 
cycloaddition. Organic Letters. 
2007;9:883-886
[17] Hudson R, Feng Y, Varma RS, 
Moores A. Bare magnetic nanoparticles: 
15
Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents
DOI: http://dx.doi.org/10.5772/intechopen.89860
Sustainable synthesis and applications 
in catalytic organic transformations. 
Green Chemistry. 2014;16:4493-4505
[18] Meldal M, Tornoe CW. Cu-catalyzed 
azide-alkyne cycloaddition. Chemical 
Reviews. 2008;108:2952-3015
[19] Hein JE, Fokin VV. Copper-
catalyzed azide-alkyne cycloaddition 
(CuAAC) and beyond: New reactivity of 
copper(I) acetylides. Chemical Society 
Reviews. 2010;39:1302-1315
[20] Jin T, Yan M, Yamamoto Y. Click 
chemistry of alkyne-azide cycloaddition 
using nano-structured copper catalysts. 
ChemCatChem. 2012;4:1217-1229
[21] Zhou Y, He T, Wang Z.  
Nanoparticles of silver oxide 
immobilized on different templates: 
Highly efficient catalyst for three-
component coupling of aldehydeamine-
alkyne. ARKIVOC. 2008;xiii:80-90
[22] Zhou X, Lu Y, Zhai L-L, Zhao Y, Liu 
Q , Sun W-Y. Propargylamines formed 
from three-component coupling 
reactions catalyzed by silver oxide 
nanoparticles. RSC Advances. 
2013;3:1732-1734
[23] Kwon SG, Hyeon T. Colloidal 
chemical synthesis and formation kinetics 
of uniformly sized nanocrystals of metals, 
oxides, and chalcogenides. Accounts of 
Chemical Research. 2008;41:1696
[24] Hu A, Yee GT, Lin W. Magnetically 
recoverable chiral catalysts immobilized 
on magnetite nanoparticles for 
asymmetric hydrogenation of aromatic 
ketones. Journal of the American 
Chemical Society. 2005;127:12486
[25] Kawamura M, Sato K. Magnetically 
separable phase-transfer catalysts. 
Chemical Communications. 
2006;45:4718
[26] Xia YN, Yang PD, Sun YG, Wu YY, 
Mayers B, Gates B, et al. One-dimensional 
nanostructures: Synthesis, 
characterization, and applications. 
Advanced Materials. 2003;15:353-389
[27] Comparelli R, Fanizza E, 
Curri ML, Cozzoli PD, Mascolo G, 
Agostiano A. UV-induced photocatalytic 
degradation of azo dyes by organic-
capped ZnO nanocrystals immobilized 
onto substrates. Applied Catalysis B: 
Environmental. 2005;60:1-11
[28] Moghaddam FM, Saeidian H. 
Controlled microwave-assisted 
synthesis of ZnO nanopowder and its 
catalytic activity for O-acylation of 
alcohol and phenol. Materials Science 
and Engineering B. 2007;139:265-269
[29] Mirjafary Z, Saeidian H, Sadeghi A, 
Moghaddam FM. ZnO nanoparticles: An 
efficient nanocatalyst for the synthesis 
of β-acetamido ketones/esters via a 
multi-component reaction. Catalysis 
Communications. 2008;9:299-306
[30] Gupta M, Paul S, Gupta R, 
Loupy A. ZnO: A versatile agent for 
benzylic oxidations. Tetrahedron 
Letters. 2005;46:4957-4960
[31] Lietti L, Tronconi E, Forzatti P. 
Surface properties of zno-based 
catalysts and related mechanistic 
features of the higher alcohol 
synthesis by FT-IR spectroscopy and 
TPSR. Journal of Molecular Catalysis. 
1989;55:43-54
[32] Sharghi H, Hosseini M. Solvent-free 
and one-step beckmann rearrangement 
of ketones and aldehydes by zinc oxide. 
Synthesis. 2002:1057
[33] Dhakshinamoorthy A, 
Visuvamithiran P, Tharmaraj V, 
Pitchumani K. Clay encapsulated ZnO 
nanoparticles as efficient catalysts for 
N-benzylation of amines. Catalysis 
Communications. 2011;16:15-19
[34] Sarvari MH, Sharghi H. Reactions 
on a solid surface. A simple, economical 
Organic Synthesis - A Nascent Relook
16
and efficient Friedel-Crafts acylation 
reaction over zinc oxide (ZnO) as a 
new catalyst. The Journal of Organic 
Chemistry. 2004;69:6953
[35] Sarvari MH. ZnO/CH3COCl: A 
new and highly efficient catalyst for 
dehydration of aldoximes into nitriles 
under solvent-free condition. Synthesis. 
2005;5:787
[36] Sarvari MH. Synthesis of 
β-aminoalcohols catalyzed by ZnO. Acta 
Chimica Slovenica. 2008;55:440
[37] Kim YJ, Varma RS. Microwave 
assisted preparation of cyclic ureas 
from diamines in the presence of 
ZnO. Tetrahedron Letters. 2004;45:7205
[38] Sarvari MH, Sharaghi H. ZnO as 
a new catalyst for N-formylation of 
amines under solvent-free conditions. 
The Journal of Organic Chemistry. 
2006;71:6652
[39] Zhang M, Wang L, Ji H, Wu B, 
Zenge X. Cumene liquid oxidation 
to cumene hydroperoxide over CuO 
nanoparticle with molecular oxygen 
under mild condition. Journal of 
Natural Gas Chemistry. 2007;16:393-417
[40] Beydoun D, Amal R, Low G, 
McEvoy S. Role of nanoparticles in 
photocatalysis. Journal of Nanoparticle 
Research. 1999;1:439-458
[41] Kassaee MZ, Masrouri H, 
Movahedi F. ZnO-nanoparticle-
promoted synthesis of 
polyhydroquinoline derivatives 
via multicomponent Hantzsch 
reaction. Monatshefte für Chemie. 
2010;141:317-322
[42] Prasad GK, Ramacharyulu PVRK, 
Singh B, Batra K, Srivastava AR, 
Ganesan K, et al. Sun light assisted 
photocatalytic decontamination 
of sulfur mustard using ZnO 
nanoparticles. Journal of Molecular 
Catalysis A: Chemical. 2011;349:55
[43] Evans BE, Rittle KE, 
Bock MG, Dipardo RM, Freidinger RM, 
Whitter WL, et al. Methods for drug 
discovery: Development of potent, 
selective, orally effective cholecystokinin 
antagonists. Journal of Medicinal 
Chemistry. 1998;31:2235
[44] Muller G. Medicinal chemistry of 
target family-directed masterkeys. Drug 
Discovery Today. 2003;8:681
[45] Bocker H, Guengerich FP.  
Oxidation of 4-aryl- and 
4-alkyl-substituted 2,6-dimethyl-
3,5-bis(alkoxycarbonyl)-1,4-
dihydropyridines by human liver 
microsomes and immunochemical 
evidence for the involvement 
of a form of cytochrome P-450. 
Journal of Medicinal Chemistry. 
1986;29(9):1596-1603
[46] Sausins A, Duburs G. Synthesis 
of 1,4-dihydropyridines by 
cyclocondensation reactions. 
Heterocycles. 1988;27:269-289
[47] Goldman S, Stoltefuss J. 1,4‐
dihydropyridines: Effects of chirality 
and conformation on the calcium 
antagonist and calcium agonist 
activities. Angewandte Chemie 
International Edition in English. 
1991;30:559-1578
[48] Bossert F, Meyer H, Wehinger E. 
4‐Aryldihydropyridines, a new class 
of highly active calcium antagonists. 
Angewandte Chemie International 
Edition in English. 1981;20:762-769
[49] Bossert F, Vater W. 
1,4-dihydropyridines--a basis for 
developing new drugs. Medicinal 
Research Reviews. 1989;9(3):291-324
[50] Buhler FR, Kiowski W. Calcium 
antagonists in hypertension. Journal of 
Hypertension. 1987;5(3):S3-S10
[51] Reid JL, Meridith PA, 
Pasanisi F. Clinical pharmacological 
17
Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents
DOI: http://dx.doi.org/10.5772/intechopen.89860
aspects of calcium antagonists and their 
therapeutic role in hypertension. Journal 
of Cardiovascular Pharmacology. 
1985;7:S18-S20
[52] Godfaid T, Miller R, Wibo M. 
Calcium antagonism and calcium entry 
blockade. Pharmacological Reviews. 
1986;38:321-327
[53] Mannhold R, Jablonka B, Voigdt W, 
Schoenafinger K, Schravan K. Calcium- 
and calmodulin-antagonism of elnadipine 
derivatives: Comparative SAR. European 
Journal of Medicinal Chemistry. 
1992;27:229-235
[54] Boer R, Gekeler V. Chemosensitizer 
in tumor therapy: New compounds 
promise better efficacy. Drugs of the 
Future. 1995;20:499-509
[55] Bretzel RG, Bollen CC, Maester E, 
Federlin KF. Nephroprotective effects 
of nitrendipine in hypertensive 
type I and type II diabetic patients. 
American Journal of Kidney Diseases. 
1993;21:54-63
[56] Bretzel RG, Bollen CC, Maester E, 
Federlin KF. Trombodipine platelet 
aggregation inhibitor antithrombotic. 
Drugs of the Future. 1992;17:465-468
[57] Sridhar R, Perumal PT. 
A new protocol to synthesize 
1,4-dihydropyridines by using 
3,4,5-trifluorobenzeneboronic acid as 
a catalyst in ionic liquid: Synthesis of 
novel 4-(3-carboxyl-1H-pyrazol-4-yl)-
1,4-dihydropyridines. Tetrahedron. 
2005;61:2465
[58] Heravi MM, Behbahani FK, 
Oskooie HA, Shoar RH. Catalytic 
aromatization of Hantzsch 
1,4-dihydropyridines by ferric 
perchlorate in acetic acid. Tetrahedron 
Letters. 2005;46:2775
[59] Moseley JD. Alternative esters in 
the synthesis of ZD0947. Tetrahedron 
Letters. 2005;46:3179
[60] Hantzsch A. Condensationprodukte 
aus aldehydammoniak und 
ketoniartigen verbindungen. Bernoulli. 
1881;14:1637-1638
[61] Loev B, Snader KM. Oxidation 
dealkylation of certain 
dihydropyridines. The Journal of 
Organic Chemistry. 1965;30:1914
[62] Alajarin R, Vaquero JJ, 
Garcia JLN, Alvarez-Builla J. Synthesis 
of 1,4-dihydropyridines under 
microwave irradiation. Synlett. 
1992:297
[63] Khadikar BM, Gaikar VG, 
Chitnavis AA. Aqueous hydrotrope 
solution as a safer medium for 
microwave enhanced Hantzsch 
dihydropyridine ester synthesis. 
Tetrahedron Letters. 1995;36:8083
[64] Ohberg L, Westman J. An efficient 
and fast procedure for the hantzsch 
dihydropyridine synthesis under 
microwave conditions. Synlett. 
2001;2001(8):1296-1298
[65] Agarwal A, Chauhan PMS. Solid 
supported synthesis of structurally 
diverse dihydropyrido[2,3-d]
pyrimidines using microwave 
irradiation. Tetrahedron Letters. 
2005;46:1345
[66] Phillips AP. Hantzsch’s pyridine 
synthesis. Journal of the American 
Chemical Society. 1949;71:4003
[67] Anderson GJR, Berkelhammer G. 
A study of the primary acid reaction 
on model compounds of reduced 
diphosphopyridine nucleotide. Journal 
of the American Chemical Society. 
1958;80:992
[68] Dolly HS, Chimni SS, 
Kumar S. Acid catalysed enamine 
induced transformations of 
1,3-dimethyl-5-formyluracil. A unique 
annulation reaction with enaminones. 
Tetrahedron. 1995;51:12775
Organic Synthesis - A Nascent Relook
18
[69] Breitenbucher JG, Figliozzi G. Solid-
phase synthesis of 4-aryl-1,4-
dihydropyridines via the Hantzsch three 
component condensation. Tetrahedron 
Letters. 2000;41:4311
[70] Kumar A, Maurya RA. Synthesis of 
polyhydroquinoline derivatives through 
unsymmetric Hantzsch reaction 
using organocatalysts. Tetrahedron. 
2007;63:1946
[71] Wang L-M, Sheng J, Zhang L, 
Han J-W, Fan Z, Tian H, et al. Facile 
Yb(OTf)3 promoted one-pot 
synthesis of polyhydroquinoline 
derivatives through Hantzsch reaction. 
Tetrahedron. 2005;61:1539
[72] Ravikumar Naik TR, Bhojya 
Naik HS, Prakash Naik HR, Bindu PJ, 
Harish BG, Krishna V. Synthesis, DNA 
binding, docking and photoclevage 
studies of novel benzo[b][1,8]
naphthyridines. Medicinal Chemistry. 
2009;5(5):411
[73] Bindu PJ, Mahadevan KM, 
Ravikumar Naik TR. Sm(III)nitrate-
catalyzed one-pot synthesis of 
furano[3,2c]-1,2,3,4-tetrahydroquinolines 
and DNA photocleavage studies. Journal 
of Molecular Structure. 2012;1020:142
[74] Bindu PJ, Mahadevan KM, 
Satyanarayan ND, Ravikumar Naik TR. 
Synthesis and DNA cleavage studies of 
novel quinoline oxime esters. Bioorganic 
& Medicinal Chemistry Letters. 
2012;22(2):898
[75] Bindu PJ, Mahadevan KM, 
Naik TRR, Harish BG. Synthesis, DNA 
binding, docking and photocleavage 
studies of 2-chloro-3-quinolinyl-
3-phenylpropen-2-ones. Medicinal 
Chemistry Communications. 
2014;5:1708
[76] Ravikumar Naik TR, Shivashankar  
SA. Heterogeneous bimetallic ZnFe2O4 
nanopowder catalyzed synthesis of 
Hantzsch 1,4-dihydropyridines in water. 
Tetrahedron Letters. 2016;57:4046-4049
[77] Janis RA, Silver PJ, Triggle DJ. Drug 
action and cellular calcium regulation. 
Aciv, Advances in Drug Research. 
1987;16:309
[78] Lavilla R. Recent developments 
in the chemistry of dihydropyridines. 
Journal of the Chemical Society, Perkin 
Transactions 1. 2002:1141
[79] Kappe CO. Biologically active 
dihydropyrimidones of the Biginelli-
type–a literature survey. European 
Journal of Medicinal Chemistry. 
2000;35:1043
[80] Varache-Lemebge M, Nuhrich A, 
Zemb V, Devaux G, Vacher P, 
Vacher AM, et al. Synthesis and activities 
of a thienyl dihydropyridine series on 
intracellular calcium in a rat pituitary 
cell line (GH3/B6). European Journal of 
Medicinal Chemistry. 1996;31:547
[81] Alker D, Campbell SF, Cross PE, 
Burges RA, Carter AJ, Gardiner DG. 
Long-acting dihydropyridine calcium 
antagonists. 4. Synthesis and structure-
activity relationships for a series of 
basic and nonbasic derivatives of 
2-[(2-aminoethoxy)methyl]-1,4-
dihydropyridine calcium antagonists. 
Journal of Medicinal Chemistry. 
1990;33:585
[82] Reddy PR, Rao KS, Satyanarayana B. 
Synthesis and DNA cleavage properties 
of ternary Cu(II) complexes containing 
histamine and amino acids. Tetrahedron 
Letters. 2006;47(41):7311-7315
[83] Reddy DS, Hosamani KM, 
Devarajegowda HC. Design, synthesis 
of benzocoumarinpyrimidine hybrids 
as novel class of antitubercular agents, 
their DNA cleavage and X-ray studies. 
European Journal of Medicinal 
Chemistry. 2015;101:705-715
19
Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents
DOI: http://dx.doi.org/10.5772/intechopen.89860
[84] Barton JK, Raphael AL. 
Photoactivated stereospecific cleavage 
of double-helical DNA by cobalt(III) 
complexes. Journal of the American 
Chemical Society. 1984;106:2466
[85] Sigman DS. Nuclease activity 
of 1,10-phenanthroline-copper ion. 
Accounts of Chemical Research. 
1986;19:180
[86] Liu C, Zhou J, Xu H. Interaction of 
the copper(II) macrocyclic complexes 
with DNA studied by fluorescence 
quenching of ethidium. Journal of 
Inorganic Biochemistry. 1998;71:1-6
[87] Suvarna S, Krishna K, Kaushik SH, 
Rijesh K, Diwakar L, Reddy GC. 
Synthesis, anticancer and antioxidant 
activities of 2,4,5-trimethoxy chalcones 
and analogues from asaronaldehyde: 
Structureeactivity relationship. 
European Journal of Medicinal 
Chemistry. 2013;62:435-442
[88] Sun C, Aspland SE, Ballatore C, 
Castillo R, Smith AB, Castellino AJ. The 
design, synthesis, and evaluation of 
two universal doxorubicin-linkers: 
Preparation of conjugates that retain 
topoisomerase II activity. Bioorganic 
& Medicinal Chemistry Letters. 
2006;16:104
[89] Zhang Y, Zheng W, Luo Q , Zhao Y, 
Zhang E, Liu S, et al. Dual-targeting 
organometallic ruthenium(ii) 
anticancer complexes bearing EGFR-
inhibiting 4-anilinoquinazoline 
ligands. Dalton Transactions. 
2015;44:13100-13111
[90] Tabassum S, Zaki M, Afzal M, 
Arjmand F. New modulated design 
and synthesis of quercetin-Cu(II)/
Zn(II)-Sn2(IV) scaffold as anticancer 
agents: In vitro DNA binding profile, 
DNA cleavage pathway and Topo-I 
activity. Dalton Transactions. 
2013;42(27):10029
[91] Taha M, Ismail NH, Khan A, 
Shah SAA, Anwar A, Halim SA, et al. 
Synthesis of novel derivatives of 
oxindole, their urease inhibition and 
molecular docking studies. Bioorganic 
& Medicinal Chemistry Letters. 
2015;25(16):3285-3289
